{Reference Type}: Journal Article
{Title}: Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia.
{Author}: Staber PB;Herling M;Bellido M;Jacobsen ED;Davids MS;Kadia TM;Shustov A;Tournilhac O;Bachy E;Zaja F;Porkka K;Hoermann G;Simonitsch-Klupp I;Haferlach C;Kubicek S;Mayerhoefer ME;Hopfinger G;Jaeger U;Dearden C;
{Journal}: Blood
{Volume}: 134
{Issue}: 14
{Year}: 10 2019 3
{Factor}: 25.476
{DOI}: 10.1182/blood.2019000402
{Abstract}: T-cell prolymphocytic leukemia (T-PLL) is a rare, mature T-cell neoplasm with a heterogeneous clinical course. With the advent of novel treatment options that will potentially change the management of patients with T-PLL, it has become necessary to produce consensus guidelines for the design and conduct of clinical trials. The T-PLL International Study group (TPLL-ISG) set out to define standardized criteria for diagnosis, treatment indication, and evaluation of response. These criteria will facilitate comparison of results from clinical trials in T-PLL, and will thus support clinical decision making, as well as the approval of new therapeutics by healthcare authorities.